NCT01985191View on ClinicalTrials.gov

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Neoplasm Malignant
Interventions
DRUG

SAR405838

"Pharmaceutical form:capsule~Route of administration: oral"

DRUG

Pimasertib

"Pharmaceutical form: capsule~Route of administration: oral"

Trial Locations (4)

94805

Investigational Site Number 250001, Villejuif

1066 CX

Investigational Site Number 528001, Amsterdam

3075 EA

Investigational Site Number 528003, Rotterdam

3584 CX

Investigational Site Number 528002, Utrecht

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01985191 - A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients | Biotech Hunter | Biotech Hunter